Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31197661 | 0.78 | MGLL (0.33) | GSK3AGSK3BMAPK1LMNA | |
| SCHEMBL11522594 | 0.70 | — | — | |
| SCHEMBL4397208 | 0.67 | LMNA (0.37) | GSK3AGSK3BGAAKDM4EATM | |
| SCHEMBL5542692 | 0.61 | GAA (0.30) | GSK3AGSK3BGAA | |
| SCHEMBL10818094 | 0.60 | ALOX5 (0.44) | GSK3AGSK3BGAAKDM4EL3MBTL1 | |
| SCHEMBL3462582 | 0.58 | SIGMAR1 (0.39) | GSK3AGSK3BGAAKDM4EHTR3E | |
| SCHEMBL7113548 | 0.57 | POLB (0.35) | GSK3AGSK3BGAAKDM4EATM | |
| SCHEMBL2466051 | 0.57 | LMNA (0.42) | GSK3AGSK3BGAAKDM4EATM | |
| SCHEMBL19143101 | 0.57 | KDM4E (0.46) | GSK3AGSK3BGAAKDM4EATM | |
| SCHEMBL24776903 | 0.55 | MGLL (0.44) | GSK3AGSK3BGAAATMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585543-A2 | CONDUCTIVE POLYMER ON A TEXTURED OR PLASTIC SUBSTRATE | Massachusetts Institute Of Technology (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011163556-A2 | CONDUCTIVE POLYMER ON A TEXTURED OR PLASTIC SUBSTRATE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2010141800-A1 | LIGHT EMITTING DEVICE INCLUDING SEMICONDUCTOR NANOCRYSTALS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100145050-A1 | ORTHOGONALLY FIXED COMPOUNDS FOR ELECTROOPTICAL APPLICATIONS | TECHNISCHE UNIVERSITAT BRAUNSCHWEIG (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1838805-B1 | ORTHOGONALLY FIXED COMPOUNDS FOR ELECTROOPTICAL APPLICATIONS | UNIV BRAUNSCHWEIG TECH (DE) | 2009-12-02 | — | — | EP | disclosed |
| EP-2011157-A4 | ELECTRONIC DEVICES CONTAINING ACENE-THIOPHENE COPOLYMERS WITH SILYLETHYNYL GROUPS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2011157-A1 | ELECTRONIC DEVICES CONTAINING ACENE-THIOPHENE COPOLYMERS WITH SILYLETHYNYL GROUPS | 3M Innovative Properties Company (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008149828-A1 | ORGANOMETALLIC COMPLEX, AND LIGHT-EMITTING MATERIA LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE AND ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008144549-A1 | ORGANIC LIGHT EMITTING DEVICES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-11-27 | — | — | WO | disclosed |
| EP-1989725-A2 | WHITE LIGHT EMITTING DEVICES | THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2005058348-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| EP-1503997-A1 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-1497393-A1 | ELECTROLUMINESCENT MATERIALS AND METHODS OF MANUFACTURE AND USE | 3M Innovative Properties Company (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1493308-A1 | LIGHT EMITTING DEVICE INCLUDING SEMICONDUCTOR NANOCRYSTALS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004096783-A1 | ETHYNYL CONTAINING ELECTRON TRANSPORT AGENTS AND THEIR USE IN ORGANIC LUMINESCENT DEVICES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004061992-A1 | ORGANIC ELECTROLUMINESCENT DEVICE AND FABRICATION METHOD THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2003097617-A1 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003089542-A1 | ELECTROLUMINESCENT MATERIALS AND METHODS OF MANUFACTURE AND USE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003084292-A1 | LIGHT EMITTING DEVICE INCLUDING SEMICONDUCTOR NANOCRYSTALS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002023784-A2 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145050-A1 | ORTHOGONALLY FIXED COMPOUNDS FOR ELECTROOPTICAL APPLICATIONS | AQP4, SLC16A3, AQP1 | GSK3A 4195/4885GSK3B 4352/4885GAA 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.